Home › Products › Oncology › Zejula 100mg Tablet
Zejula 100mg Tablet
Salt Composition: NIRAPARIB
- Manufacturer: GLAXO SMITHKLINE PHARMACEUTICALS LTD
- Pack Size: 56 TABLET(s) IN A BOTTLE
- Dosage Form: TABLET
- Strength: 100MG
- Prescription Required
- Storage: Store at room temperature (15–30°C). Protect from moisture and direct sunlight. Keep the medicine in its original packaging until use. Keep out of reach of children.
₹488209.00₹574363.13
Inclusive of all taxes
Product Introduction
Zejula 100mg Tablet is a prescription medicine used in the treatment of certain types of cancers, primarily ovarian, fallopian tube, and peritoneal cancers. It belongs to the class of Poly (ADP-ribose) polymerase (PARP) inhibitors. By blocking PARP enzymes, which are essential for repairing damaged DNA in cancer cells, Zejula 100mg Tablet prevents cancer cells from repairing themselves, leading to their death. Zejula tablet is available in oral tablet form, making it convenient for long-term use as maintenance therapy after initial cancer treatment. However, patients taking Zejula 100mg Tablet require regular monitoring of blood counts, blood pressure, and heart health, as it may increase the risk of anaemia, hypertension, or other complications. It should not be used during pregnancy or breastfeeding, and patients with pre-existing heart disease, blood disorders, or uncontrolled hypertension must inform their doctor before starting therapy.
Uses
Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Maintenance treatment of recurrent ovarian cancer.
How it works
Cancer cells rely heavily on DNA repair mechanisms to survive and grow. Zejula 100mg Tablet inhibits the PARP enzyme, which plays a key role in repairing damaged DNA. When PARP is blocked, DNA damage accumulates in cancer cells, leading to their death. This is especially effective in tumours with BRCA gene mutations or homologous recombination deficiencies (HRD), but Zejula Cap 100mg is also beneficial in patients without these mutations.
Side Effects
Zejula ovarian cancer side effects are: Serious: Severe anaemia (unusual tiredness, pale skin, shortness of breath) Thrombocytopenia (unexplained bleeding or bruising) Hypertension (severe headache, chest pain, blurred vision) Allergic reactions (rash, swelling, difficulty breathing) Bone marrow suppression (persistent fever, frequent infections) Rare cases of myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) Common: Nausea and vomiting Fatigue Loss of appetite Constipation Insomnia Stomach pain Headache or dizziness
References
- Mansoor Raza Mirza et al., “Zejula 100mg Tablet Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer,” The New England Journal of Medicine, [Dec 2016], showing significant improvement in progression-free survival with Zejula 100mg Tablet https://www.nejm.org/doi/full/10.1056/NEJMoa1611310
- Bradley J. Monk et al., “Zejula 100mg Tablet in Patients with Newly Diagnosed Advanced Ovarian Cancer,” The New England Journal of Medicine, [Jun 2019], PRIMA trial establishing Zejula 100mg Tablet as frontline maintenance therapy https://www.nejm.org/doi/full/10.1056/NEJMoa1910962
- U.S. Food and Drug Administration (FDA), “FDA approves Zejula 100mg Tablet for first-line maintenance of advanced ovarian cancer,” [April 2020] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-Zejula 100mg Tablet-first-line-maintenance-advanced-ovarian-cancer
- European Medicines Agency (EMA), “Zejula (Zejula 100mg Tablet): EPAR – Product Information,” [Accessed Sept 2025], regulatory details for EU approval https://www.ema.europa.eu/en/medicines/human/EPAR/zejula
Safety Advice
Pregnancy: Unsafe Zejula 100mg Tablet can harm the unborn baby. Do not use during pregnancy. Inform your doctor if you are pregnant or planning to conceive.
Lungs: Consult Doctor
Breastfeeding: Unsafe Avoid breastfeeding while taking Zejula 100mg Tablet and for at least 1 month after the last dose
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.